Erste Asset Management’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.43M Buy
+41,000
New +$1.24M 0.01% 420
2026
Q1
Sell
-21,700
Closed -$604K 611
2025
Q4
$604K Hold
21,700
0.01% 476
2025
Q3
$519K Hold
21,700
0.01% 473
2025
Q2
$365K Hold
21,700
﹤0.01% 683
2025
Q1
$482K Hold
21,700
0.01% 433
2024
Q4
$577K Hold
21,700
0.01% 429
2024
Q3
$544K Hold
21,700
0.01% 429
2024
Q2
$520K Hold
21,700
0.01% 415
2024
Q1
$737K Hold
21,700
0.01% 395
2023
Q4
$639K Hold
21,700
0.01% 407
2023
Q3
$521K Hold
21,700
0.01% 404
2023
Q2
$690K Hold
21,700
0.01% 392
2023
Q1
$654K Hold
21,700
0.01% 402
2022
Q4
$840K Hold
21,700
0.02% 378
2022
Q3
$1.03M Buy
21,700
+6,800
+46% +$388K 0.02% 354
2022
Q2
$602K Hold
14,900
0.01% 411
2022
Q1
$886K Buy
14,900
+6,400
+75% +$420K 0.02% 369
2021
Q4
$672K Sell
8,500
-6,500
-43% -$557K 0.01% 400
2021
Q3
$1.31M Buy
15,000
+8,500
+131% +$854K 0.03% 313
2021
Q2
$720K Hold
6,500
0.01% 376
2021
Q1
$492K Sell
6,500
-8,000
-55% -$761K 0.01% 386
2020
Q4
$1.29M Buy
+14,500
New +$713K 0.04% 314

Other funds holding BEAM

Erste Asset Management's BEAM Position: Q2 2026 in Review

Erste Asset Management opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 41,000 shares worth $1.43M. The stake represents 0.01% of the portfolio and ranks #420 among its holdings. This is a return to the name: Erste Asset Management previously reported a position in BEAM as recently as Q4 2025.

Erste Asset Management first reported a position in BEAM in Q4 2020 and has held it in 22 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Erste Asset Management held 41,000 shares of Beam Therapeutics worth $1.43M as of Q2 2026.
  • Beam Therapeutics was a new Erste Asset Management position in Q2 2026.
  • Beam Therapeutics made up 0.01% of Erste Asset Management's portfolio in Q2 2026, its #420 holding.
  • Erste Asset Management first reported a position in Beam Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.